Blog
About

27
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Experimental therapy of human glioma by means of a genetically engineered virus mutant.

      Science (New York, N.Y.)

      Animals, Antiviral Agents, pharmacology, Brain Neoplasms, therapy, Cells, Cultured, Dose-Response Relationship, Drug, Foscarnet, Glioma, Mice, Mice, Nude, Mutagenesis, Phosphonoacetic Acid, analogs & derivatives, Simplexvirus, genetics, immunology, Thymidine Kinase, Vidarabine, Viral Vaccines, therapeutic use

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Malignant gliomas are the most common malignant brain tumors and are almost always fatal. A thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas. In cell culture, dlsptk killed two long-term human glioma lines and three short-term human glioma cell populations. In nude mice with implanted subcutaneous and subrenal U87 human gliomas, intraneoplastic inoculation of dlsptk caused growth inhibition. In nude mice with intracranial U87 gliomas, intraneoplastic inoculation of dlsptk prolonged survival. Genetically engineered viruses such as dlsptk merit further evaluation as novel antineoplastic agents.

          Related collections

          Author and article information

          Journal
          1851332

          Comments

          Comment on this article